NeuroPace (NASDAQ:NPCE) Given New $14.00 Price Target at JPMorgan Chase & Co.

NeuroPace (NASDAQ:NPCE) had its target price increased by equities research analysts at JPMorgan Chase & Co. from $9.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 12.99% from the stock’s current price.

Separately, Wells Fargo & Company lowered their target price on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.50.

NeuroPace Price Performance

Shares of NPCE traded up $0.92 on Tuesday, reaching $12.39. The stock had a trading volume of 56,166 shares, compared to its average volume of 95,486. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.15. The firm has a market capitalization of $369.82 million, a PE ratio of -12.39 and a beta of 2.05. The firm has a 50-day moving average of $8.42 and a 200 day moving average of $7.59. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period in the previous year, the firm earned ($0.28) EPS. Sell-side analysts expect that NeuroPace will post -1 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Ltd. Kck sold 4,910 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60. Following the completion of the transaction, the insider now owns 5,540,104 shares of the company’s stock, valued at approximately $36,897,092.64. This represents a 0.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 257,590 shares of company stock valued at $1,437,916 in the last quarter. 22.20% of the stock is currently owned by company insiders.

Institutional Trading of NeuroPace

A number of institutional investors and hedge funds have recently made changes to their positions in NPCE. Millennium Management LLC grew its position in NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after acquiring an additional 80,324 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of NeuroPace in the 2nd quarter valued at about $257,000. Geode Capital Management LLC grew its holdings in shares of NeuroPace by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after purchasing an additional 25,330 shares during the period. Acadian Asset Management LLC increased its position in NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after purchasing an additional 21,703 shares in the last quarter. Finally, Barclays PLC raised its holdings in NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.